“Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s768, https://doi.org/10.25251/bqftmw67.